Quick Glance: AstraZeneca surpasses estimates with strong sales of cancer and diabetes drugs
- Drugmaker reports a 38% increase in earnings as it expands its genomic medicine business.
- Strong sales of drugs for cancer and diabetes helped AstraZeneca exceed expectations in Q2.
- Pascal Soriot, AstraZeneca's CEO, announced that eight medicines generated over $1bn in revenue in H1.
- AstraZeneca plans to acquire Pfizer's early-stage portfolio of gene therapies in a deal worth up to $1bn.
The most popular articles of the week on boerse-online:
⚫ Allianz share: forecast confirmed http://ow.ly/oaXf50J7ebc
⚫ Bayer stock: setback for comeback ... Show more http://ow.ly/f2Yt50J7ebb http://ow.ly/oanK50J7eb7
Baths: Heavy casualties and understaffing
Diverse bathing landscape remains, but restrictions are to be expected
First came Corona ... Show more https://presse.karlsruhe.de/db/stadtzeitung/jahr2022/woche19/bader_starke_verluste_und_personalmangel.html
Despite the considerable influence of the corona pandemic, the SCP07 was able to achieve positive operating results in the past financial years ... Show more https://bit.ly/SCP07_Bilanz
Lauterbach's pandemic expertise brought him to the ministry. But there is a lot of skepticism. Lauterbach is not a typical politician ... https://bit.ly/3ywItFI